Intravenous immunoglobulin protects against experimental thrombotic microangiopathy

Kidney International

Volumn 60, Issue 3, 2001, Pages 1018-1025

  Jefferson, J Ashley ^a,b   Suga, Shin Ichi ^a,b   Kim, Yoon Goo ^a,b   Pippin, Jeffrey ^a,b   Gordon, Katherine L ^a,b   Johnson, Richard J ^a,b   Couser, William G ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Capillary thrombosis; Complement; Glomerular endothelial cell; Hemolytic uremic syndrome; Kidney injury

Indexed keywords

ANTIBODY; BUFFER; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; PHOSPHATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY PERFUSION; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; HEMATOCRIT; HISTOPATHOLOGY; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; RAT; RENAL ARTERY; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNINEPHRECTOMY;

EID: 0035722160     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0600031018.x     Document Type: Article

References (47)

1. Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy
2. Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9
3. A new model of renal microvascular endothelial injury
4. CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats
5. Modulation of mono-nuclear phagocyte function by intravenous gamma-globulin
6. Idiopathic thrombocytopenic purpura (ITP): Immunomodulation by intravenous immunoglobulin (IVIg)
7. Anti-idiotypes against autoantibodies to procoagulant factor VIII (VIII:C) in intravenous immunoglobulins
8. Pooled human IgG modulates cytokine production in lymphocytes and monocytes
9. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
10. High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway
11. High doses of immuno-globulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes
12. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the IG isotype and its C1 binding properties
13. Antibodies defining rat endothelial cells: RECA-1, a pan-endothelial cell-specific monoclonal antibody
14. Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis
15. Purification of IgG mono-clonal antibody by caprylic acid precipitation
16. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
17. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
18. A role for P-selectin in neutrophil and platelet infiltration in immune complex glomerulonephritis
19. C5b-9 membrane attack complex mediates endothelial cell apoptosis in experimental glomerulonephritis
20. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface
21. Complement-mediated regulation of tissue factor activity in endothelium
22. Transient perturbation of endothelial integrity induced by natural antibodies and complement
23. Pooled human immunoglobulin (PHIG) inhibits the binding of antiendothelial cell antibodies to endothelial cells
24. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
25. Modulation of complement-mediated immune damage by intravenous immune globulin
26. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation
27. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation
28. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: Attenuation of acute, complement-dependent immune damage in a guinea pig model
29. The pathophysiology of the hemolytic uremic syndrome
30. A Western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies
31. Postpartum hemolytic uremic syndrome associated with antiphospholipid antibodies: A case report and review of the literature
32. Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome
33. Haemolytic-uraemic syndrome: Basic science
34. Familial, recurrent haemolytic-uraemic syndrome with hypocomplementaemia
35. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities: Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura
36. Breakdown products of C3 and factor B in hemolytic-uremic syndrome
37. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome
38. The complement system in hemolytic-uremic syndrome in childhood
39. The hemolytic uremic syndrome, with positive immunofluorescence studies
40. Adult hemolytic uremic syndrome with renal arteriolar deposition of IgM and C3
41. Familial hemolytic-uremic syndrome and homozygous factor H deficiency
42. Genetic studies into inherited and sporadic hemolytic uremic syndrome
43. Treatment of thrombotic thrombocytopenic purpura with intravenous gamma globulin
44. Inefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome
45. Anticytotoxin-neutralizing antibodies in immune globulin preparations: Potential use in hemolytic-uremic syndrome
46. Adverse effects of intravenous immunoglobulin therapy
47. Inhibition of complement-mediated immune hemolysis by peptides derived from the constant domain of immunoglobulin